Mechanisms of Healing and Intracardiac Integration

Results At 3 days in dogs, atrial surfaces were covered by fibrin, which sealed gaps between the LA wall and the device and filled the LA appendage cavity. At 45 days, endothelial cells covered the endocardial surface with underlying smooth muscle cells that sealed the device-LA interface. Regions with prior thrombus were replaced by endocardium surrounding the device membrane. Disorganized thrombus remained in the LAA body and at the periphery near the appendage walls. Mild inflammation was observed as thrombus resorbed. By 90 days, a complete endocardial lining covered the former LAA ostium. Organizing thrombus had become connective tissue, with no residual inflammation. The human necropsy hearts had similar findings. In these 4 hearts (139, 200, 480, and 852 days after implant), the ostial fabric membrane was covered with endocardium. The appendage surface contained organizing thrombus with minimal inflammation. Organizing fibrous tissue was inside the LAA cavity, prominent near the atrial wall. The LAA interior contained organizing thrombus. Conclusions This intracardiac device integration study delineated healing stages of early thrombus deposition, thrombus organization, inflammation and granulation tissue, final healing by connective tissue, and endocardialization without inflammation. These observations may yield insight into cellular healing processes in other cardiac devices. (J Am Coll Cardiol Intv 2010;3:870 –7) © 2010 by the American College of Cardiology Foundation

[1]  Maurice Buchbinder,et al.  Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial , 2009, The Lancet.

[2]  I. Palacios,et al.  Left atrial appendage exclusion using an Amplatzer device. , 2009, International journal of cardiology.

[3]  I. Michel-Behnke,et al.  Immunohistochemical Characterization of Neotissues and Tissue Reactions to Septal Defect–Occlusion Devices , 2009, Circulation. Cardiovascular interventions.

[4]  R. Virmani,et al.  A review of current devices and a look at new technology: drug-eluting stents , 2009, Expert review of medical devices.

[5]  S. Lerakis,et al.  Left atrial appendage exclusion system for stroke prevention in atrial fibrillation: a percutaneous device delivery approach. , 2008, Minerva Cardioangiologica : a Journal on Cardiovascular Pathophysiology, Clinical Medicine and Therapy.

[6]  R. Franke,et al.  Post-Mortem Analysis of a Left Atrial Appendage Occlusion Device (PLAATO™) in a Patient with Permanent Atrial Fibrillation , 2008, Cardiology.

[7]  Renu Virmani,et al.  Pathophysiology of vascular healing and stent mediated arterial injury. , 2008, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[8]  C. Ruiz,et al.  Percutaneous transcatheter left atrial appendage exclusion in atrial fibrillation. , 2008, The Journal of invasive cardiology.

[9]  R. Virmani,et al.  Patent Foramen Ovale Closure by Radiofrequency Thermal Coaptation: First Experience in the Porcine Model and Healing Mechanisms Over Time , 2007, Circulation.

[10]  R. Virmani,et al.  Vascular Pathology of Drug-Eluting Stents , 2007, Herz Kardiovaskuläre Erkrankungen.

[11]  G. Schuler,et al.  Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation. , 2007, Journal of the American College of Cardiology.

[12]  K. Sung,et al.  Time-related histopathologic analyses of immunologically untreated porcine valved conduits implanted in a porcine-to-goat model. , 2007, Artificial organs.

[13]  J. Carrozza,et al.  Suture‐mediated closure of a patent foramen ovale during surgery without cardiopulmonary bypass , 2006, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[14]  Michael Joner,et al.  Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. , 2006, Journal of the American College of Cardiology.

[15]  P. Wohlsein,et al.  Interventional atrial septal defect closure using a totally bioresorbable occluder matrix: development and preclinical evaluation of the BioSTAR device. , 2006, Journal of the American College of Cardiology.

[16]  H. Sievert,et al.  Transcatheter occlusion of the left atrial appendage for stroke prevention , 2005, Expert review of cardiovascular therapy.

[17]  R. Virmani,et al.  Drug-eluting stents: caution and concerns for long-term outcome , 2004, Coronary artery disease.

[18]  R. Virmani,et al.  Percutaneous Left Atrial Appendage Occlusion (PLAATO) for Preventing Cardioembolism: First Experience in Canine Model , 2002, Circulation.

[19]  T. Henry,et al.  Pathophysiology of coronary artery restenosis. , 2002, Reviews in cardiovascular medicine.

[20]  K. Jenkins,et al.  Healing response to the clamshell device for closure of intracardiac defects in humans , 2001, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[21]  V. Ferrans,et al.  Wound healing in the mitral valve. , 2000, The Journal of heart valve disease.

[22]  P. Serruys,et al.  Histological changes in the aortic valve after balloon dilatation: evidence for a delayed healing process. , 1992, British heart journal.

[23]  A. Gotlieb,et al.  In Vitro Repair of the Wounded Porcine Mitral Valve , 1988, Circulation research.

[24]  N. Braunwald,et al.  Acceleration of tissue ingrowth on materials implanted in the heart. , 1976, The Annals of thoracic surgery.

[25]  K. Little Mechanisms of incorporation of homografts and heterografts. , 1970, Proceedings of the Royal Society of Medicine.

[26]  Kirklin Jw,et al.  Surgical healing of the atrioventricular leaflets: an experimental study. , 1957 .